Compare Envarsus XR vs Prograf head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

Studies of stable kidney transplant recipients (KTR) converted from twice-daily Prograf to once-daily Envarsus (LCP-Tacro) showed greater bioavailability, a more consistent concentration profile, noninferior efficacy and similar safety and with lower total daily dose (TDD) for Envarsus.

Phase 3, double-blind, randomized, multicenter trial to compare the efficacy and safety of ENVARSUS XR vs Prograf® in adult de novo transplant recipients of a living or deceased donor kidney transplant (except for donation after cardiac death) (N=543).

Purpose: Immediate release tacrolimus (Prograf®) is the cornerstone treatment post lung transplantation (LTx). Extended release tacrolimus (Envarsus®) has a higher bioavailability resulting in lower peak and more stable serum levels.

2015年6月24日 · At equivalent exposure, Envarsus achieves at least a 30% dose reduction requirement and a substantively lower peak blood concentration (p=<0.005) compared to the two comparator products.

2014年7月15日 · Envarsus patients attained targeted troughs within 1 day of first dose; Prograf levels were achieved within 4 to 7 days. From month 3 onward, Envarsus KTR required a lower daily dose vs. Prograf KTR with similar trough levels, …

Compare Envarsus XR vs Tacrolimus head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

Envarsus is a novel once-daily, MeltDose formulation of Tac with greater bioavailability, less peak and trough-to-peak fluctuations, and similar efficacy and safety vs. twice-daily Tac (Prograf).

Study Design: Phase 3, double-blind, randomized, multicenter trial to compare the efficacy and safety of ENVARSUS XR vs Prograf in adult de novo transplant recipients of a living or deceased donor kidney transplant (except for donation after cardiac death;